Browsing by Author "Nanteza, Angel"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The association of cognitive impairment with quality of life and functional impairment in Ugandan frst-episode psychosis patients: a cross sectional study
    (Health and Quality of Life Outcomes, 2022) Mwesiga, Emmanuel K.; Ssemata, Andrew S.; Gumikiriza, Joy; Nanteza, Angel; Nakitende, Anne Jacqueline; Nakku, Juliet; Akena, Dickens; Nakasujja, Noeline
    Cognitive impairment is common in first-episode psychosis patients and often associated with poor quality of life and functional impairment. However, most literature on this association is from high income countries and not low resource countries like Uganda. We aimed to determine the association between cognitive impairment with quality of life and functional impairment in Ugandan first-episode psychosis patients.
  • Thumbnail Image
    Item
    Evaluating Construct and Criterion validity of NeuroScreen in Assessing Neurocognition among Hospitalized Ugandan First-episode Psychosis Patients
    (Schizophrenia Research: Cognition, 2023) Asiedu, Nana; Mwesiga, Emmanuel Kiiza; Akena, Dickens; Gumikiriza-Onoria, Joy Louise; Nanteza, Angel; Nakku, Juliet; Nakasujja, Noeline; Ssembajjwe, Wilber; Ferraris, Christopher M.; Santoro, Anthony F.; Robbins, Reuben N.
    Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. NeuroScreen is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of NeuroScreen to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda. We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed NeuroScreen and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on NeuroScreen and the MCCB. A ROC curve determined sensitivity and specificity of NeuroScreen to detect NCI as determined by MCCB criterion. There was a large, statistically significant correlation between overall performance on NeuroScreen and the MCCB [r(112) = 0.64, p < .001]. Small to large correlations were found between tests in the MCCB and NeuroScreen batteries. The ROC curve of NeuroScreen performance to detect MCCB-defined NCI had an area under curve of 0.80 and optimal sensitivity and specificity of 83 % and 60 %, respectively. There was a moderate positive correlation between overall performance on both batteries. NeuroScreen shows promise as a valid assessment battery to assess neurocognition and detect NCI in FEP patients in Uganda. Further studies of NeuroScreen in healthy individuals and in a range of mental disorders are recommended.